• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗心律失常药物反应性及诊断至消融时间对持续性心房颤动导管消融术后结局的影响

Effects of antiarrhythmic drug responsiveness and diagnosis-to-ablation time on outcomes after catheter ablation for persistent atrial fibrillation.

作者信息

Kim Hong-Ju, Kim Daehoon, Kim Kipoong, Choi Sung Hwa, Kim Moon-Hyun, Park Je-Wook, Yu Hee Tae, Kim Tae-Hoon, Uhm Jae-Sun, Joung Boyoung, Lee Moon-Hyoung, Pak Hui-Nam

机构信息

Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital Yonsei University College of Medicine Seoul Republic of Korea.

Division of Cardiology, Department of Internal Medicine Yeungnam University College of Medicine Daegu Republic of Korea.

出版信息

J Arrhythm. 2024 Jul 2;40(4):867-878. doi: 10.1002/joa3.13104. eCollection 2024 Aug.

DOI:10.1002/joa3.13104
PMID:39139899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11317675/
Abstract

BACKGROUND

The impact of delaying atrial fibrillation catheter ablation (AFCA) for antiarrhythmic drug (AAD) management on the disease course remains unclear. This study investigated AFCA rhythm outcomes based on the diagnosis-to-ablation time (DAT) and AAD responsiveness in participants with persistent AF (PeAF).

METHODS

We included data from 1038 AAD-resistant PeAF participants, all of whom had a clear time point for AF diagnosis, especially PeAF at diagnosis time, and had undergone an AFCA for the first time. Participants who experienced recurrences of paroxysmal type on AAD therapy were analyzed as a cohort of AAD-partial responders; those maintaining PeAF on AAD were AAD-non-responders. We determined the DAT cutoff for best discriminating long-term rhythm outcomes using a maximum log-likelihood estimation method based on the Cox proportional hazard regression model.

RESULTS

Of the participants (79.8% male; median age 61), 806 (77.6%) were AAD-non-responders. AAD-non-responders had a higher body mass index and a larger left atrial diameter than AAD-partial-responders. They also had a higher incidence of AF recurrence after AFCA (adjusted hazard ratio 1.75, 95% confidence interval 1.33-2.30; log-rank  < .001) compared to AAD-partial-responders. The maximum log-likelihood estimation showed bimodal cutoffs at 22 and 40 months. The optimal DAT cutoff rhythm outcome was 22 months, which discriminated better in the AAD-partial-responders than in the AAD-non-responders.

CONCLUSIONS

Both DAT and AAD responsiveness influenced AFCA rhythm outcomes. Delaying AFCA to a DAT of longer than 22 months was inadvisable, particularly in the participants in whom PeAF was changed to paroxysmal AF during AAD therapy.

摘要

背景

抗心律失常药物(AAD)治疗时延迟心房颤动导管消融(AFCA)对疾病进程的影响尚不清楚。本研究在持续性房颤(PeAF)患者中,基于诊断至消融时间(DAT)和AAD反应性,调查了AFCA的节律结果。

方法

我们纳入了1038例对AAD耐药的PeAF患者的数据,所有患者均有明确的房颤诊断时间点,尤其是诊断时为PeAF,且首次接受AFCA。在AAD治疗期间经历阵发性房颤复发的患者作为AAD部分反应者队列进行分析;在AAD治疗期间维持PeAF的患者为AAD无反应者。我们基于Cox比例风险回归模型,使用最大对数似然估计方法确定了最佳区分长期节律结果的DAT临界值。

结果

在这些患者中(79.8%为男性;中位年龄61岁),806例(77.6%)为AAD无反应者。AAD无反应者的体重指数和左心房直径高于AAD部分反应者。与AAD部分反应者相比,他们在AFCA后房颤复发的发生率也更高(调整后风险比1.75,95%置信区间1.33 - 2.30;对数秩检验P <.001)。最大对数似然估计显示在22个月和40个月时有双峰临界值。最佳的DAT临界值节律结果为22个月,在AAD部分反应者中比在AAD无反应者中区分效果更好。

结论

DAT和AAD反应性均影响AFCA的节律结果。将AFCA推迟至DAT超过22个月是不可取的,尤其是在AAD治疗期间PeAF转变为阵发性房颤的患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/6099e53bfac0/JOA3-40-867-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/f16cdf1b36d0/JOA3-40-867-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/b8551f4f5ae1/JOA3-40-867-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/ca6a1b1f8641/JOA3-40-867-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/9101741e3c00/JOA3-40-867-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/6099e53bfac0/JOA3-40-867-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/f16cdf1b36d0/JOA3-40-867-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/b8551f4f5ae1/JOA3-40-867-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/ca6a1b1f8641/JOA3-40-867-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/9101741e3c00/JOA3-40-867-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69ed/11317675/6099e53bfac0/JOA3-40-867-g003.jpg

相似文献

1
Effects of antiarrhythmic drug responsiveness and diagnosis-to-ablation time on outcomes after catheter ablation for persistent atrial fibrillation.抗心律失常药物反应性及诊断至消融时间对持续性心房颤动导管消融术后结局的影响
J Arrhythm. 2024 Jul 2;40(4):867-878. doi: 10.1002/joa3.13104. eCollection 2024 Aug.
2
Persistent atrial fibrillation over 3 years is associated with higher recurrence after catheter ablation.持续3年以上的持续性心房颤动与导管消融术后较高的复发率相关。
J Cardiovasc Electrophysiol. 2020 Feb;31(2):457-464. doi: 10.1111/jce.14345. Epub 2020 Jan 15.
3
Sex difference in atrial fibrillation recurrence after catheter ablation and antiarrhythmic drugs.导管消融和抗心律失常药物治疗后心房颤动复发的性别差异。
Heart. 2023 Mar 10;109(7):519-526. doi: 10.1136/heartjnl-2021-320601.
4
Atrial fibrillation and the risk of ischaemic strokes or intracranial haemorrhages: comparisons of the catheter ablation, medical therapy, and non-atrial fibrillation population.心房颤动与缺血性卒中和颅内出血的风险:导管消融、药物治疗与非心房颤动人群的比较。
Europace. 2021 Apr 6;23(4):529-538. doi: 10.1093/europace/euaa235.
5
Effect of preprocedural pharmacologic cardioversion on pulmonary vein isolation in patients with persistent atrial fibrillation.术前药物复律对持续性心房颤动患者肺静脉隔离的影响。
Heart Rhythm. 2021 Sep;18(9):1473-1479. doi: 10.1016/j.hrthm.2021.04.027. Epub 2021 Apr 28.
6
Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.使用苄普地尔进行术后抗心律失常药物治疗对持续性心房颤动导管消融术后维持窦性心律的影响。
J Cardiol. 2016 Sep;68(3):229-35. doi: 10.1016/j.jjcc.2015.09.012. Epub 2015 Dec 3.
7
Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation-Insights from the German Ablation Registry.房颤导管消融术后抗心律失常药物治疗——来自德国消融登记处的见解。
Pharmacol Res Perspect. 2021 Dec;9(6):e00880. doi: 10.1002/prp2.880.
8
Clinical Outcomes of Computational Virtual Mapping-Guided Catheter Ablation in Patients With Persistent Atrial Fibrillation: A Multicenter Prospective Randomized Clinical Trial.持续性心房颤动患者计算机虚拟标测引导下导管消融的临床结局:一项多中心前瞻性随机临床试验
Front Cardiovasc Med. 2021 Dec 8;8:772665. doi: 10.3389/fcvm.2021.772665. eCollection 2021.
9
Sex differences in mapping and rhythm outcomes of a repeat atrial fibrillation ablation.重复心房颤动消融的映射和节律结果的性别差异。
Heart. 2021 Dec;107(23):1862-1867. doi: 10.1136/heartjnl-2020-318282. Epub 2021 Jan 22.
10
Catheter Ablation vs. Anti-Arrhythmic Drugs as First-Line Treatment in Symptomatic Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.导管消融与抗心律失常药物作为有症状阵发性心房颤动一线治疗的比较:一项随机临床试验的系统评价和荟萃分析
Front Cardiovasc Med. 2021 May 21;8:664647. doi: 10.3389/fcvm.2021.664647. eCollection 2021.

引用本文的文献

1
Impact of catheter ablation timing according to duration of atrial fibrillation history on arrhythmia recurrences and clinical outcomes: a meta-analysis.根据房颤病史时长进行导管消融时机选择对心律失常复发及临床结局的影响:一项荟萃分析
Europace. 2025 Jun 3;27(6). doi: 10.1093/europace/euaf110.

本文引用的文献

1
Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences.早期与延迟心房颤动导管消融对心房心律失常复发的影响。
Eur Heart J. 2023 Jul 14;44(27):2447-2454. doi: 10.1093/eurheartj/ehad247.
2
Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.导管消融术采用肺静脉隔离与不隔离左心房后壁对持续性心房颤动患者房性心律失常复发的影响:CAPLA 随机临床试验。
JAMA. 2023 Jan 10;329(2):127-135. doi: 10.1001/jama.2022.23722.
3
Progression of Atrial Fibrillation after Cryoablation or Drug Therapy.
冷冻消融或药物治疗后心房颤动的进展。
N Engl J Med. 2023 Jan 12;388(2):105-116. doi: 10.1056/NEJMoa2212540. Epub 2022 Nov 7.
4
Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK.抗心律失常药物和导管消融对房颤患者生存的影响:基于英国 199433 例新发房颤患者的人群研究。
Europace. 2023 Feb 16;25(2):351-359. doi: 10.1093/europace/euac155.
5
Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.MRI 引导下纤维消融与常规导管消融对持续性心房颤动患者心房颤动复发的影响:DECAAF II 随机临床试验。
JAMA. 2022 Jun 21;327(23):2296-2305. doi: 10.1001/jama.2022.8831.
6
Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation.恢复窦性心律可逆转心房颤动患者的心脏重构并减少瓣膜反流。
J Am Coll Cardiol. 2022 Mar 15;79(10):951-961. doi: 10.1016/j.jacc.2021.12.029.
7
Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study.治疗时机和节律控制策略对心房颤动患者的影响:全国队列研究。
BMJ. 2021 May 11;373:n991. doi: 10.1136/bmj.n991.
8
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study.导管消融治疗心房颤动后痴呆症减少:一项全国性队列研究。
Eur Heart J. 2020 Dec 14;41(47):4483-4493. doi: 10.1093/eurheartj/ehaa726.
9
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.心房颤动患者的早期节律控制治疗。
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
10
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.